share_log

B of A Securities Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $56

Benzinga ·  Jan 2 10:48

B of A Securities analyst Jason Gerberry maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $52 to $56.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment